Skip to main content

New Products: Eastern Biotech's Trigene; UK NHS's Cancer Test; COSMIC


Eastern Biotech in Dubai is now offering BGI Health's non-invasive sequencing-based prenatal test for Down syndrome under the name Trigene. The test, which BGI calls NIFTY for noninvasive fetal trisomy, is based on a shotgun sequencing strategy.

The UK's National Health Service has launched a 46-gene cancer panel developed by the University of Oxford and Oxford University Hospitals NHS Trust. Currently, the test is being run out of the Oxford Biomedical Research Center's Molecular Diagnostics Center, but will eventually be offered broadly within the NHS. The £300 ($453) test is based on Life Technologies' Ion AmpliSeq Cancer panel and runs on the Ion Torrent PGM. It was developed under the UK's Stratified Medicine Program, through a tumor profiling initiative funded by the Technology Strategy Board. The test was initially made available at the beginning of the year through the University of Oxford (CSN 1/2/2013).

The Wellcome Trust Sanger Institute has released version 64 of COSMIC, the Catalog of Somatic Mutations in Cancer. The latest release includes the full curation of gene fusions CIC-DUX4 and ACTB-GLI1 in solid tumors. It has also added 12 whole-genome sequencing publications, bringing the total number of whole-genome sequencing samples to 5,023.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.